- Home
- PRT vs XGN Comparison
PRT vs XGN Comparison
Compare PRT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- XGN
- Stock Information
- Founded
- PRT 2017
- XGN 2002
- Country
- PRT United States
- XGN United States
- Employees
- PRT N/A
- XGN N/A
- Industry
- PRT Oil & Gas Production
- XGN Medical Specialities
- Sector
- PRT Energy
- XGN Health Care
- Exchange
- PRT Nasdaq
- XGN Nasdaq
- Market Cap
- PRT 48.8M
- XGN 49.4M
- IPO Year
- PRT N/A
- XGN 2019
- Fundamental
- Price
- PRT $3.94
- XGN $2.71
- Analyst Decision
- PRT
- XGN Buy
- Analyst Count
- PRT 0
- XGN 1
- Target Price
- PRT N/A
- XGN $7.00
- AVG Volume (30 Days)
- PRT 36.3K
- XGN 26.8K
- Earning Date
- PRT 11-12-2024
- XGN 11-11-2024
- Dividend Yield
- PRT 10.95%
- XGN N/A
- EPS Growth
- PRT N/A
- XGN N/A
- EPS
- PRT 0.44
- XGN N/A
- Revenue
- PRT $6,201,668.00
- XGN $56,660,000.00
- Revenue This Year
- PRT N/A
- XGN $9.98
- Revenue Next Year
- PRT N/A
- XGN $13.63
- P/E Ratio
- PRT $8.96
- XGN N/A
- Revenue Growth
- PRT N/A
- XGN 7.05
- 52 Week Low
- PRT $3.58
- XGN $1.30
- 52 Week High
- PRT $6.36
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- PRT 48.77
- XGN 41.39
- Support Level
- PRT $3.86
- XGN $2.90
- Resistance Level
- PRT $3.99
- XGN $3.03
- Average True Range (ATR)
- PRT 0.10
- XGN 0.19
- MACD
- PRT -0.00
- XGN -0.04
- Stochastic Oscillator
- PRT 44.44
- XGN 12.80
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive 80% of the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.